Retatrutide for Type 2 Diabetes: The Next-Gen Option
Beyond weight loss, retatrutide shows exceptional promise for type 2 diabetes control with A1C reductions of 2-2.5% in Phase 2 trials.
Key Diabetes Benefits
- • A1C reduction: 2.0-2.5% average drop
- • Weight loss: 24-28% (critical for diabetes reversal)
- • Insulin sensitivity: Significant improvement
- • Beta cell function: Enhanced insulin secretion
Retatrutide vs Current Diabetes Medications
| Medication | A1C Reduction | Weight Loss |
|---|---|---|
| Retatrutide | 2.0-2.5% | 24-28% |
| Mounjaro (tirzepatide) | 1.8-2.4% | 15-22.5% |
| Ozempic (semaglutide) | 1.5-1.8% | 10-15% |
| Metformin | 1.0-1.5% | 2-3% |
Key insight: Retatrutide's massive weight loss (24-28%) is what drives superior diabetes control. Weight loss IS diabetes treatment.
Current Options While Waiting for Retatrutide
Mounjaro: Best Option Available NOW
Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes and delivers 80-90% of retatrutide's benefits:
- ✅ A1C reduction: 1.8-2.4% (comparable to retatrutide)
- ✅ Weight loss: 15-22.5% (75-85% of retatrutide's results)
- ✅ Available NOW through telehealth ($179-499/mo)
- ✅ Can switch to retatrutide when approved
Don't Wait—Start Controlling Diabetes TODAY
Mounjaro: 1.8-2.4% A1C reduction + 15-22.5% weight loss. Available NOW.
Get Started →